Conference Coverage

EASD: Alirocumab lipid-lowering benefits extend to patients with high-risk diabetes

Publish date: October 1, 2015

 

AT EASD 2015

References

The potential for alirocumab to reduce cardiovascular events will be investigated in the large, phase III ODYSSEY Outcomes study. This trial is currently recruiting and aims to accrue around 18,000 high-risk patients including those with diabetes. The study is projected to complete by the end of 2017.

Pages

Recommended Reading

EASD: Pre-pregnancy weight, not gestational gain, affects later diabetes risk
MDedge Endocrinology
Long-acting insulin degludec – and degludec combo drug – win FDA nod
MDedge Endocrinology
ICAAC: 2015 brings three major systematic reviews of diabetic foot infection therapy
MDedge Endocrinology
Metformin associated with small height gain in children
MDedge Endocrinology
Evidence links common endocrine-disrupting chemicals to obesity, diabetes, reproductive disorders
MDedge Endocrinology
ADA proposes new standards for students with diabetes
MDedge Endocrinology
Severity of obesity matters in pediatric population
MDedge Endocrinology
EASD: Liraglutide lowers HbA1c when added to insulin in longstanding type 2 diabetes
MDedge Endocrinology
EASD: Metformin-induced B12 deficiency linked to diabetic neuropathy
MDedge Endocrinology
EASD: Diabetes doubles death risk from many causes
MDedge Endocrinology